Tuesday, May 21, 2024 NIAID Research Team Develops 2nd Model of Crimean-Congo Fever A scanning electron micrograph shows Crimean-Congo hemorrhagic fever viral particles in magenta budding from the surface of a patient's cultured epithelial cells. Credit: NIAID A NIAID research team has developed an additional nonhuman primate study model for Crimean-Congo hemorrhagic fever (CCHF), providing an alternative for development of vaccines and therapeutics. They hope the work, published in npj Vaccines, will lead to a widely available replicating RNA-based vaccine that they are testing against CCHF. The WHO lists CCHF virus as a priority pathogen for development of vaccines. In some outbreaks CCHF has had a case fatality rate up to 40%. Cynomolgus macaques (CM) are the preferred model available to study how the virus causes infection and disease in people. But during the COVID-19 pandemic, CMs were prioritized for other research, and NIAID scientists sought to develop an alternative model using rhesus macaques (RM) to continue vaccine work. RMs infected with CCHFV developed mild-to-moderate disease, similar to the CM model and consistent with disease in humans. The scientists then showed that the experimental vaccine provided six infected RMs with a protective immune response that controlled CCHF virus. The results are consistent with their findings using CMs and support continued advancement of the vaccine into human trials. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107